Adoption of cell therapy in the treatment of Covid-19 patients can reduce the risk of death by 60 percent. This has been confirmed in a research. The systematic review and meta-analysis included 195 trials of advanced cell therapies targeting COVID-19. The trials were conducted in 30 countries between January 2020 and December 2021. Also 26 trials were conducted with results published by July 2022.
The findings of the study, conducted by researchers at the University of São Paulo (USP) in Brazil in partnership with colleagues in Germany and the United States, were reported in the journal Frontiers in Immunology. Cell therapy has advanced significantly in recent years and has been used to treat cancer and auto-immune, cardiovascular and infectious diseases. During the pandemic, it was used to treat COVID-19 in several trials.
Otavio Cabral-Marques, a professor at the USP Medical School, said, “Our study is the first to review all the information on these experiences scattered around the world and verify through meta-analysis. It explains how cell therapy Works when used to treat COVID-19 and related complications. Cell therapy uses stem cells from the patient (autologous) or a donor (allogeneic). The cells are cultured in the laboratory before they are modified. is modified.
According to research, the most commonly used cells in COVID-19 treatment trials during this period were multipotent mesenchymal stem (stromal) cells from connective tissue. According to the research authors, despite the focus on cell therapy, emphasis should be placed on vaccination safety.
–IANS
MKS